The first prospective trial for von Hippel-Lindau disease: pazopanib

Rachel H Giles*, Sven Gläsker

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

Original languageEnglish
Pages (from-to)1267-1269
Number of pages3
JournalLANCET ONCOLOGY
Volume19
Issue number10
Early online date17 Sept 2018
DOIs
Publication statusPublished - Oct 2018

Keywords

  • Journal Article
  • Pyrimidines
  • Prospective Studies
  • Sulfonamides
  • Humans
  • von Hippel-Lindau Disease

Cite this